We comprehensively screened 68 breast/ovarian cancer families for small-range mutations, 221 families for LGRs, and 1,022 unselected breast cancer cases for Colombian founder mutations in BRCA1/2. This evidence concerns the gene BRCA1 and ovarian cancer.